Literature DB >> 6253241

Angiotensin II and renal hypertension in dog, rat and man: effect of converting enzyme inhibition.

A B Atkinson, J J Brown, R Fraser, A F Lever, J J Morton, A J Riegger, J I Robertson.   

Abstract

The role of the renin-angiotensin system in the pathogenesis of one-clip, two-kidney hypertension has been studied in man, dog and rat. Particular attention has been paid to peripheral plasma concentrations of angiotensin II in different circumstances; angiotensin II infusion has been combined with radioimmunoassay to construct angiotensin II/blood pressure dose-response curves. The effect of converting enzyme inhibitors has been studied, precautions being taken to avoid obtaining falsely high values for plasma angiotensin II because of cross-reaction with angiotensin I in these circumstances. The initial phase of one-clip, two-kidney hypertension is attributable to the direct pressor effect of the immediate rise in plasma angiotensin II. Subsequently, plasma angiotensin II is relatively lower, although blood pressure remains high. This upward resetting of the plasma angiotensin II/blood pressure relationship can be mimicked by infusing angiotensin II chronically at low dose. After reconstruction of a stenosed renal artery, or excision of a post-stenotic kidney, the angiotensin II/blood pressure relationship returns slowly to normal. In this second phase of one-clip, two-kidney hypertension, the long-term administration of saralasin, or of converting enzyme inhibitor, can also return arterial pressure to normal; brief administration of these drugs is less effective or ineffective. The results are compatible with, although they do not conclusively establish, an important slow pressor action of the renin-angiotensin system in the second phase of one-clip, two-kidney hypertension. This provides a rational basis for the use of captopril clinically in this condition.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253241     DOI: 10.3109/10641968009037127

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 0148-3927            Impact factor:   1.749


  6 in total

1.  Mechanism of Ang II involvement in activation of NF-κB through phosphorylation of p65 during aging.

Authors:  Ji Min Kim; Hyoung-Sam Heo; Young Mi Ha; Byeong Hyeok Ye; Eun Kyeong Lee; Yeon Ja Choi; Byung Pal Yu; Hae Young Chung
Journal:  Age (Dordr)       Date:  2011-02-12

2.  Adverse host factors exacerbate occult HIV-associated nephropathy.

Authors:  Dileep Kumar; Divya Salhan; Sandeep Magoon; Deepti D Torri; Swapna Sayeneni; Ankita Sagar; Anshu Bandhlish; Ashwani Malhotra; Praveen N Chander; Pravin C Singhal
Journal:  Am J Pathol       Date:  2011-08-24       Impact factor: 4.307

Review 3.  The renin-angiotensin system in the control of systemic arterial pressure.

Authors:  A B Ribeiro; O Kohlmann; M A Saragoça; O Marson; O L Ramos
Journal:  Drugs       Date:  1985       Impact factor: 9.546

4.  Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.

Authors:  A B Atkinson; J J Morton; J J Brown; D L Davies; R Fraser; P Kelly; B Leckie; A F Lever; J I Robertson
Journal:  Br Heart J       Date:  1980-09

5.  Silencing of hypoxia-inducible factor-1α gene attenuates chronic ischemic renal injury in two-kidney, one-clip rats.

Authors:  Zhengchao Wang; Qing Zhu; Pin-Lan Li; Romesh Dhaduk; Fan Zhang; Todd W Gehr; Ningjun Li
Journal:  Am J Physiol Renal Physiol       Date:  2014-03-12

6.  Sulforaphane Prevents Angiotensin II-Induced Testicular Cell Death via Activation of NRF2.

Authors:  Yonggang Wang; Hao Wu; Ying Xin; Yang Bai; Lili Kong; Yi Tan; Feng Liu; Lu Cai
Journal:  Oxid Med Cell Longev       Date:  2017-01-16       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.